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1003-94 Rheolytic Thrombectomy for the Treatment of Acute 
Myocardial Infarction in Patients With Angiographic 
Large Thrombus Burden: One-Year Results of the 
VeGAS 2 Acute Myocardial Infarction Registry
Jose A. Silva, Stephen R. Ramee, David Cohen, Joseph P. Carrozza, Jeffrey J. Popma, 
Kim Dandreo, Alexandra A. Lansky, Donald S. Baim, Barry S. George, Daniel J. 
McCormick, Cindy M. Setum, Richard E. Kuntz, The VeGAS 2 Investigators, Ochsner 
Clinic Foundation, New Orleans, LA
Background. The treatment of acute myocardial infarction (MI), in patients (pts) with
angiographic evidence of large thrombus burden is difficult. There are scarce data in the
literature addressing the optimal management of this high-risk patient population.
Methods and Results. This prospective study enrolled 107 pts (age, 61 ± 12 years, 71%
males) presenting with acute ST elevation MI within 24 hours of symptoms onset and
angiographic evidence of thrombus. The culprit lesion was located in a native coronary
artery in 74.5%, and in a bypass graft in 25.5%. Abciximab was used in 42.1% of the pts.
Thrombus area decreased from 97 ± 67 mm2 at baseline to 17 ± 11 mm2 post thrombec-
tomy, to 3 ± 12 mm2 after final treatment. TIMI 3 coronary flow was obtained in 78% after
thrombectomy and 87% after final treatment. Procedure success (residual diameter
stenosis < 50%, and TIMI 3 flow post-procedure in the absence of in-hospital death,
emergent CABG and recurrent Q-wave MI) was obtained in 77% of the patients. Bleeding
and vascular complications occurred in 13% and 11% respectively, abrupt or subacute
closure in 6.6%, and distal embolization in 6.8%. The in-hospital death and major cardio-
vascular events (death, Q-wave MI, surgical or percutaneous target lesion revasculariza-
tion [TLR] or CVA) (MACE) rates were 7.8% and 13% respectively. There were no
additional MACE at 30-follow-up after discharge. At one-year follow-up there was an
additional 4% mortality, 7.4% TLR, and 1.8% CVA , but no Q-wave MI.
Conclusion. Patients presenting with acute MI and angiographic evidence of large
thrombus burden are at higher risk for mortality and MACE compared with historical con-
trols. Rheolytic thrombectomy is very effective in removing thrombus and restoring TIMI 3
coronary flow in this high-risk patient population.
1003-95 Thrombus Aspiration for the Treatment of No-Reflow 
Phenomenon Complicating Primary Angioplasty for 
Acute Myocardial Infarction
Imad Sheiban, Claudio Moretti, Kumar Prathap, Filippo Sciuto, Andra Gagnor, Pierluigi 
Omedè, Alessandra Truffa, Walter Grosso Marra, Ahmed Shoheib, Maria Teresa 
Lucciola, Gianpaolo Trevi, University of Torino, Torino, Italy
Background: Primary angioplasty (PCI) for acute myocardial infarction (AMI) can be com-
plicated by no-reflow or slow-flow phenomenon in nearly 20% of patients. It’s not clear
which is the best strategy to use when such phenomenon occurs. Intracoronary adenos-
ine and GP IIb/IIIa antagonists have been suggested but their efficacy is not well estab-
lished. In this study we report our experience with the use of thrombus aspiration as an
approach for the treatment of no-reflow complicating primary PCI for AMI.
Methods: Among 239 consecutive primary PCI for AMI performed in our Center, 46
(19%) were complicated by no-reflow or slow-flow phenomenon. All pts received intracor-
onary GP IIb/IIIa antagonist (abiciximab) soon after culprit lesion was crossed by the
guide wire. No-reflow or slow-flow phenomenon occurred soon after balloon inflation or
stent deployment at the site of target lesion. Intracoronary adenosine (45 to 60 ug ) was
given in all 46 pts but no persistent improvement was observed. Thus , thrombus aspira-
tion by Rescue system ( Boston Scientific ) or by Diver CE catheter (Invatec srl) was
attempted in all 42 pts. At least three passages of the aspiration catheter along the culprit
vessel were performed in all pts.
Results: Blood flow was restored in 38 patients (82%) with TIMI II/III flow. In 20 pts
(52.6%) thrombotic material was aspirated from the culprit vessel as was confirmed by
histological analysis. In 6 pts a persistent TIMI I flow was observed after repeated aspira-
tion. No material was aspirated from the culprit vessel in these pts. In 2 pts thrombus
aspiration was not successful (persistent no-reflow). No procedural complications device-
related occurred . All pts were discharged within 7 days following the procedure. Clinical
follow-up was available in all patients . All were event free at 7± 3 months .
Conclusions: These data suggest that no-reflow phenomenon during primary-PCI in AMI
pts can be related to massive microembolization of thrombus fragments which might also
increase blood viscosity contributing to no-reflow phenomenon. Aspiration of thombotic
debris and blood from the treated vessel seems to be an effective approach to restore
blood flow and confers an excellent clinical outcome.
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1021-77 Diabetic Patients With Acute Coronary Syndromes Were 
Undertreated and Had Worse One-Year Outcome
Raymond T. Yan, Andrew T. Yan, Mary Tan, Lawrence Leiter, Chi-Ming Chow, David H. 
Fitchett, Ronald Fowlis, Irene Janzen, Anatoly Langer, Shaun G. Goodman, Canadian 
Heart Research Centre, Toronto, ON, Canada, University of Toronto, Toronto, ON, 
Canada
Background: Previous studies reported different characteristics, management and out-
come between diabetic and non-diabetic patients with myocardial infarction (MI). How-
ever, the relationship between diabetes and the entire spectrum of acute coronary
syndromes (ACS) is less clear.
Methods: The ACS Registry was a prospective observational study enrolling less
selected patients with suspected ACS from 51 Canadian centres. In-hospital data were
recorded on standard case report forms and one-year outcome was ascertained by stan-
dardized telephone interviews. We examined patients with confirmed ACS by pre-existing
diabetic status for differences in treatment and outcome.
Results: Of 4578 ACS patients, 1149 (25.1%) had diabetes; they were older, had more
cardiovascular risk factors, comorbidities and prior revascularization. (See Table) 
In multivariable analyses controlling for baseline characteristics, diabetes was indepen-
dently associated with higher 1-year mortality (odds ratio 1.52; 95% CI: 1.18 to1.95; 
P=0.001); this did not change significantly after further adjustment for use of medications 
and revascularization.
Conclusions: Diabetic patients with ACS represented a higher risk subgroup with more 
comorbidities and prior revascularization, but were less likely to receive effective medica-
tions or be considered for revascularization. In view of their two-fold increase in mortality, 
there remains an opportunity to optimize the use of evidence-based therapies in diabetic 
patients.
1021-78 Increased In-Hospital Mortality After Acute Myocardial 
Infarction in Patients With Impaired Fasting Glucose
Marianne Zeller, Marie-Claude Brindisi, Gilles Dentan, Yves Laurent, Jean-Claude Beer, 
Luc Janin-Manificat, Hamid Makki, Isabelle L'Huillier, Jack Ravisy, Mohamed Jolak, Jean-
Eric Wolf, Bruno Verges, Yves Cottin, The RICO Survey Working Group, University 
Hospital, Dijon, France
Objectives : In-hospital mortality after acute MI has not yet been evaluated in patients
belonging to the new category of Impaired Fasting Glucose level (IFG), as defined by the
American Diabetes Association. Methods : Between 1rst January 2001 and 31rst July
2003, all patients hospitalized with acute MI in one region of eastern France participating
to RICO survey were included in the study. Fasting blood glucose was measured <3 days
after admission. Patients were grouped based on FG concentration : Diabetes Mellitus
(DM) (FG > 7 mm/L or clinical history of DM) ; IFG (FG 6.1 to 7 mmole/L) ; NFG (normal
FG < 6.1 mmole/L). Results : Among the 999 included in the study, 381 (38%) had DM,
145 (15%) IFG and 473 (47%) NFG. Age, cardiovascular risk factors, renal function and
MI characteristics were not different between IFG and NFG patients. There was a 2 fold
increase of in-hospital mortality in IFG group when compared to normal glucose group (8
vs 4 %, p<0.001). A significant increase in cardiogenic shock (12 vs 6%, p<0.001) and in
ventricular arrhythmia (15 vs 9%, p<0.001) was observed in IFG group, as compared to
NFG group. Data from the mutivariate analysis showed that increased cardiogenic shock
(p=0.007) and ventricular arrhythmia (p=0.014) mostly explained augmented in-hospital
mortality in patients with IFG. In our population, IFG, after adjustment for potential con-
founding factors (age, sex, anterior location, LVEF, CK, reperfusion, multivessel disease
and cardiogenic shock), was an independent predictive factor for cardiogenic shock
Non-diabetic
(N=3429)
Diabetic
(N=1149)
P-value
In-hospital Management (%)
Catheterization 41.0 36.4 0.003
PCI 18.0 12.7 <0.001
Thrombolytics/1°PCI (eligible patients) 62.8 50.3 <0.001
Aspirin 93.2 88.9 <0.001
Heparin 91.4 89.3 0.032
Glycoprotein IIb/IIIa inhibitor 7.6 5.2 0.005
Outcome (%)
In-hospital mortality 1.8 3.9 <0.001
1-year mortality 7.9 14.4 <0.001
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(p=0.0079). Conclusion : Our data in unselected population of MI patients indicate for
the first time that IFG is associated with an increased mortality rate, which is mainly due
to an higher risk for developing cardiogenic shock during in-hospital stay .
1021-97 Impact of Diabetes Mellitus on Thrombolysis in 
Myocardial Infarction Risk Score, Procedural Utilization, 
and Clinical Outcomes in Minorities and Women as 
Compared to White Men With Non-ST-Segment 
Elevation Acute Coronary Syndrome
Muhammad Rizwan Khalid, Fawad Kazi, Justin Brezina Lundbye, Anita M. Kelsey, 
Raymond G. McKay, Roger Mennett, William E. Boden, University of Connecticut Health 
Center, Farmington, CT, Hartford Hospital, Hartford, CT
Introduction: It is well-recognized that diabetics with coronary heart disease , compared
to non-diabetics, are at significantly increased risk for subsequent cardiac events, but it is
unclear whether diabetics who present with non-ST-segment elevation (NSTE) acute cor-
onary syndrome (ACS) have differential rates of procedural utilization, TIMI Risk Score
(TRS) and clinical outcomes among various gender and racial subsets. Accordingly, the
purpose of the present study was to assess TRS, procedural utilization rates of cardiac
catheterization, and clinical outcomes using composite major adverse clinical events
(MACE) for diabetic and non-diabetic subsets of whites, non-whites, men and women
patients hospitalized with NSTE ACS.
Methods: A total of 2,432 NSTE ACS patients could be classified according to the pub-
lished TIMI risk score. Clinical outcomes using a MACE composite (death, MI, stroke,
need for urgent revascularization) were assessed for diabetic and non-diabetic subsets of
varying race and gender.
Results: Diabetics presented with a significantly higher TRS when compared to non-dia-
betics (4.02 vs. 3.56; P<0.001). Non-diabetics underwent more cardiac interventions
compared to diabetics (P<0.05). However, as expected, diabetics were more likely to
experience MACE (P<0.05) when compared to non-diabetics during follow-up ranging
from 30-180 days. Diabetics who did not undergo cardiac catheterization had a signifi-
cantly higher incidence of MACE (P<0.01) compared to non-diabetics, but there was no
significant gender and racial differences in MACE rates in the diabetic subgroup.
Conclusion: Although diabetic patients who present with NSTE ACS have significantly
higher TIMI Risk Scores at hospitalization and higher MACE during follow-up compared
to non-diabetics, our single-site experience revealed that there were no significant gen-
der or racial differences noted among white and non-white men or women. Paradoxically,
we noted that diabetic patients with NSTE ACS were less likely to undergo cardiac cath-
eterization than non-diabetics, but importantly, diabetics who did not undergo cardiac
catheterization appeared to fare worse than those who underwent intervention.
1021-98 Is Metabolic Dysfunction Equivalent to Diabetes as a 
Prognostic Marker in Acute Coronary Syndrome?
Pedro Araujo Goncalves, Jorge Ferreira, Luis Raposo, Carlos Aguiar, Ricardo Seabra-
Gomes, Hospital de Santa Cruz, Carnaxide, Portugal
Background: Diabetes mellitus (D) is a known prognostic marker in patients with acute
coronary syndromes (ACS). Recently, a constellation of lipid and non lipid risk factor
linked to insulin resistance was described and termed metabolic syndrome. We have pre-
viously demonstrated the independent prognostic value of a metabolic score (MS), but Its
interaction with D, as a prognostic marker in ACS, is not yet established.
Methods: We studied 302 patients with non-ST segment elevation ACS. A MS was calcu-
lated using the following variables collected on admission: obesity (BMI>30Kg/m2);
Blood pressure>130/85mmHg; Triglycerides>150mg/dl; HDL<40mg/dl (or <50mg/dl in
women); blood glucose >or= 110mg/dl. With the cut-off identified for the MS (>3 vari-
ables), we divided our population into 4 groups: D & MS; D & No MS; No D & MS; No D &
No MS. The endpoint used was the combined incidence of death and myocardial infarc-
tion at 1 year follow-up.
Results: Patients D & MS (n=30 ) had the highest study endpoint (23.3%), and the lowest
incidence was 10.3% for No D & No MS (n=204). The incidence of the study endpoint
was similar in the other 2 groups: 22.7% for ND & MS (n=22) and 21.7% for D & NMS
(n=46).
Conclusions: The presence of metabolic dysfunction in non-diabetic patients, was asso-
ciated to a poorer prognosis, as observed in diabetic patients. In patients with diabetes,
detection of metabolic dysfunction, as evaluated with the best cut-off for this score,
seems to add no aditional prognostic information.
1021-99 Metabolic Syndrome: A Major Risk Factor for Acute 
Myocardial Infarction in Patients < 45 Years of Age
Carlo Luciano, Jacqueline Hulford, Arif Abdullah, Stuart Zarich, Bridgeport Hospital, 
Bridgeport, CT, Yale University School of Medicine, New Haven, CT
Introduction: Premature coronary artery disease (CAD) is not fully explained by tradi-
tional global risk scores. Less than 25% of young adults with acute myocardial infarction
(MI) meet NCEP III criteria for pharmacotherapy. As insulin resistance is associated with
an increased risk of myocardial infarction (MI), we hypothesized that the metabolic syn-
drome (MS) is a major unrecognized risk factor for MI in young patients. Methods: We
studied 196 consecutive patients (<45yrs old) with acute MI treated at Bridgeport Hospi-
tal from January 1999 through July 2003. MI was defined as both ST elevation or non-ST
elevation MI by the usual criteria. MS was defined according to NCEP III guidelines (> 3
of five criteria with a body mass index >30kg/m2 substituted for waist circumference).
Results: For the entire cohort the mean age was 41.3 years, with a BMI of 29.8, LDL of
124 mg/dl, HDL of 36 mg/dl and triglycerides of 216 mg/dl. Of the 165 patients in whom
all 5 criteria for MS were evaluable at or before the time of MI, 63(38%) met the diagnos-
tic criteria for the MS in the absence of diabetes (DM). An additional 38 patients (23%)
had newly diagnosed or previously recognized DM. A history of cigarette use was seen
more frequently in non-MS as compared to MS patients (81% vs 66%; p=0.01), while a
family history of accelerated CVD, total cholesterol, and LDL levels were similar in both
groups. Only 19% met MS criteria based on an elevated fasting glucose. The mean 10
year Framingham risk score in non-diabetics was 9.3% (only 17.1% had scores greater
than 20%). Conclusion: MS and/or overt DM are present in nearly 2/3 of young patients
with acute MI. The presence of the MS should alert physicians to the need for aggressive
risk factor and lifestyle modifications, even in the absence of high global risk scores.
1021-100 Metabolic Syndrome: An Underecognized Risk Factor 
for Myocardial Infarction in the Young
Patrick J. Curran, Eugene H. Chung, Manish S. Chauhan, Christopher T. Pyne, Thomas 
C. Piemonte, David E. Gossman, James Waters, Seth Bilazarian, Khether Raby, Nabila 
Riskala, Richard W. Nesto, Lahey Clinic, Burlington, MA
Background: Risk factors for coronary heart disease (CHD) typically associated with
acute myocardial infarction (MI) in the young (< 45yrs of age) are smoking and familial
hypercholesterolemia. We hypothesized that metabolic syndrome (MS) is an underrecog-
nized major risk factor in these patients.
Methods: We studied 132 consecutive young patients with acute MI (ST and non ST ele-
vation) treated with primary percutaneous intervention at Lahey Clinic from June 2001 to
May 2003. Of the 132 patients studied, 85 had all 5 necessary variables to determine the
presence of metabolic syndrome. Metabolic syndrome was defined by meeting 3 (or
greater) of 5 criteria as outlined by NCEP. Body Mass Index (BMI) greater than 28.8kg/
m2 was substituted for waist circumference.
Results: 50 of 85 (58.8%) patients met the NCEP diagnostic criteria for metabolic syn-
drome. Of these 50 patients, 4 had prior history of diabetes. Twelve (26%) new diag-
noses of diabetes were made in those with metabolic syndrome. Of the other 35 patients,
two had a prior history of diabetes and two new diagnoses of diabetes were made. The
mean Framingham Risk Score for those patients with MS was 6 and for those without MS
was 5.
Conclusion: Metabolic syndrome is an underrecognized global risk factor for the develop-
ment of myocardial infarction. Metabolic syndrome is highly prevalent in young patients
with MI. Conventional risk assessment tools may not adequately identify “global” coro-
nary risk in such patients.
